* Newstin.com is for sale! * After achieving our strategic milestone, we are offering for sale: Newstin.com and all 14 related domains featuring 1 million unique visitors per month + continuously updated news database of 37 million articles in 12 world languages from 166,000 global and weighted sources + 2.1 billion metadata * To seize this unique chance, contact invest@newstin.com. * Newstin.com is for sale! *

Sanofi

                   
marketwatch.com: Chart of IMCL marketwatch.com

Eli Lilly to acquire ImClone for $6.5 billion

marketwatch.com
2 hrs ago 16 related
        

Eli Lilly to acquire ImClone for $70 a share Bid tops Bristol-Myers offer of $62 a share By Val Brickates Kennedy, MarketWatch Lilly said its offer represents a 51% premium to ImClone's closing stock price on July 30, the day...

add comment

Pharmaceuticals: Near Term Movers Based On FDA Decision Dates (at Seeking Alpha)

yahoo.com
8 hrs ago 2 related
        

by: Mike Havrilla posted on: October 06, 2008 | about stocks: Some likely near-term movers on the FDA's decision date calendar for 70 different items (click to enlarge, left) include Cypress Bioscience + partner Forest Labs...

add comment
                   

‘Cosby' star educates public about little-known disease

sacbee.com
Oct 3, 2008 1 related
        

By JAWEED KALEEM - Yet what Rashad never considered is that he may have had Peripheral Artery Disease, a relatively unknown blood vessel condition that affects 8 million Americans, or about 1 in 40 adults. Miami ranks No. 18 on...

add comment
yahoo.com: Zacks Investment Research yahoo.com

Sanofi: Long-Term Generic Impact (Zacks.com)

yahoo.com
Oct 3, 2008
        

Friday October 3, 4:23 pm ET By Brian Marckx, CFA Sanofi-Aventis ADR (NYSE: SNY - News ), located in France, develops and manufactures pharmaceutical products, primarily for sale in the prescription drug market. The company,...

add comment
yahoo.com: merck taranabant obesity yahoo.com

Merck Weighs In On Antiobesity Drug

injuryboard.com
Oct 3, 2008 28 related
        

LEARN MORE Merck & Co. stock watch Injuryboard news on Merck Injuryboard news on obesity IMAGE SOURCE: © iStockPhoto / diet / author: saluha Drug maker Merck & Co (MRK) is pulling plans to introduce an antiobesity drug. The New...

add comment

UPDATE 1-EU says Zentiva/Sanofi deal notification incomplete

finance.cz
Oct 3, 2008 1 related
        

BRUSSELS/The notification to EU competition regulators of plans by French pharmaceuticals producer Sanofi-Aventis to buy Czech generic drugmaker Zentiva is incomplete, the European Commission said. The...

add comment

BRIEF-Sanofi to give EU more information on Zentiva bid

finanznachrichten.de
Oct 3, 2008
        

PARIS, Oct 3 (Reuters) - Sanofi-Aventis SA : * French drugmaker said it was planning to give the European Union more information about its bid for Czech group Zentiva. * Sanofi added that it was sticking to its Zentiva bid...

add comment

Crucell reports positive results from Phase II rabies study

pharmaceutical-business-review.com
Oct 3, 2008 1 related
        

Biopharma company Crucell has announced positive preliminary results of the first Phase II clinical study of its investigational rabies monoclonal antibody combination, which started on March 31, 2008 in the US.

add comment
                   

Licensure of a Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated...

cdc.gov
Oct 2, 2008 1 related
        

On June 20, 2008 the Food and Drug Administration (FDA) licensed a combined diphtheria and tetanus toxoids and acellular pertussis adsorbed (DTaP), inactivated poliovirus vaccine (IPV), and Haemophilus influenzae type b...

add comment
                   

Lilly reportedly in talks to buy ImClone for $6.1 billion

marketwatch.com
Oct 2, 2008 13 related
        

Eli Lilly & Co. is in advanced talks to buy the cancer-drug developer ImClone Systems for $70 a share, or $6.1 billion, The Wall Street Journal reported on Thursday, citing people familiar with the matter.

add comment
1 2 3 4 5 next »